Display options
Cite
Kimura A, Kitamura K, Ailiken G, et al. . Oncotarget. 2017;8(40):67955-67965doi: 10.18632/oncotarget.19061.
Kimura, A., Kitamura, K., Ailiken, G., Satoh, M., Minamoto, T., Tanaka, N., Nomura, F., & Matsushita, K. (2017). . Oncotarget, 8(40), 67955-67965. https://doi.org/10.18632/oncotarget.19061
Kimura, Asako, et al. "." Oncotarget vol. 8,40 (2017): 67955-67965. doi: https://doi.org/10.18632/oncotarget.19061
Kimura A, Kitamura K, Ailiken G, Satoh M, Minamoto T, Tanaka N, Nomura F, Matsushita K. . Oncotarget. 2017 Jul 07;8(40):67955-67965. doi: 10.18632/oncotarget.19061. eCollection 2017 Sep 15. PMID: 28978087; PMCID: PMC5620227.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 07;8(40):67955-67965. doi: 10.18632/oncotarget.19061. eCollection 2017 Sep 15.

[No title available]

Oncotarget

Asako Kimura, Kouichi Kitamura, Guzhanuer Ailiken, Mamoru Satoh, Toshinari Minamoto, Nobuko Tanaka, Fumio Nomura, Kazuyuki Matsushita

Affiliations

  1. Department of Medical Technology and Sciences, Narita School of Health Sciences, International University of Health and Welfare, Chiba-ken, Japan.
  2. Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan.
  3. Division of Laboratory Medicine, Chiba University Hospital, Chiba, Japan.
  4. Division of Clinical Mass Spectrometry and Clinical Genetics, Chiba University Hospital, Chiba, Japan.
  5. Division of Translational and Clinical Oncology and Surgical Oncology, Cancer Research Institute, Kanazawa University and Hospital, Kanazawa, Japan.

PMID: 28978087 PMCID: PMC5620227 DOI: 10.18632/oncotarget.19061

Abstract

The switch of pyruvate kinase (PK) M1 to PKM2 is pivotal for glucose metabolism in cancers. The PKM1/M2 shift is controlled by the alternative splicing of two mutually exclusive exons in the PKM gene. PKM1 is expressed in differentiated tissues, whereas PKM2 is expressed in cancer tissues. This study revealed that the haplodeficiency of FUSE-binding protein (FBP)-interacting repressor (FIR), a transcriptional repressor of the

Keywords: FUSE-binding protein-interacting repressor; LC-MS/MS; pyruvate kinase M2; six-plex tandem mass tags labeling; thymic lymphoma

Conflict of interest statement

CONFLICTS OF INTEREST We have no conflicts of interest to declare.

References

  1. J Biol Chem. 1990 Oct 25;265(30):18538-45 - PubMed
  2. Cancer Res. 2010 Nov 15;70(22):8977-80 - PubMed
  3. Hepatology. 2014 Oct;60(4):1241-50 - PubMed
  4. Mol Cancer Res. 2012 Jun;10 (6):787-99 - PubMed
  5. Nat Commun. 2016 Feb 04;7:10615 - PubMed
  6. J Biol Chem. 2009 Jan 2;284(1):630-9 - PubMed
  7. Mol Cancer Res. 2013 Jul;11(7):689-98 - PubMed
  8. Immunol Rev. 2015 Jan;263(1):257-78 - PubMed
  9. Cancer Sci. 2013 Feb;104(2):149-56 - PubMed
  10. J Pathol. 2015 Nov;237(3):390-401 - PubMed
  11. Cancer Cell. 2015 Oct 12;28(4):405-406 - PubMed
  12. Methods. 2011 Aug;54(4):361-9 - PubMed
  13. J Biol Chem. 1996 Aug 30;271(35):21439-45 - PubMed
  14. Oncotarget. 2015 Mar 10;6(7):5102-17 - PubMed
  15. Nat Struct Mol Biol. 2012 Feb 05;19(3):346-54 - PubMed
  16. Oncotarget. 2015 May 30;6(15):13006-18 - PubMed
  17. Anal Chem. 2008 Apr 15;80(8):2921-31 - PubMed
  18. Int J Proteomics. 2012;2012:623190 - PubMed
  19. Proteomics. 2013 Aug;13(15):2339-50 - PubMed
  20. Nature. 2015 Sep 17;525(7569):384-8 - PubMed
  21. Nat Rev Cancer. 2015 Oct;15(10):574-5 - PubMed
  22. Science. 2009 May 22;324(5930):1029-33 - PubMed
  23. Biochim Biophys Acta. 2014 Dec;1846(2):285-96 - PubMed
  24. Nature. 2010 Jan 21;463(7279):364-8 - PubMed
  25. Cancer Res. 2006 Feb 1;66(3):1409-17 - PubMed
  26. Mol Cell. 2000 Feb;5(2):331-41 - PubMed

Publication Types